行情

ORMP

ORMP

Oramed
NASDAQ

实时行情|Nasdaq Last Sale

3.190
+0.100
+3.24%
交易中 15:00 04/08 EDT
开盘
3.110
昨收
3.090
最高
3.210
最低
3.092
成交量
1.97万
成交额
--
52周最高
6.05
52周最低
2.317
市值
7,366.98万
市盈率(TTM)
-4.4220
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ORMP价格均价为10.50,最高价位20.00,最低价为5.50。

EPS

ORMP 新闻

更多
  • Oramed Patent in Canada Allowed for Oral Delivery of Proteins
  • PR Newswire · 1天前
  • Oramed Pharmaceuticals Issues CEO Shareholder Letter Providing Business Update Amid COVID-19
  • PR Newswire · 04/01 13:40
  • NVAX, INSG among premarket gainers
  • Seeking Alpha - Article · 04/01 13:20
  • Oramed CEO Sends Letter To Shareholders, Highlights Oral Insulin FDA End-Of-Phase 2 Meeting, NASH Intermediate Study Data Expected This Qtr., Co. Has ~$50M In Cash
  • Benzinga · 04/01 12:44

所属板块

生物技术和医学研究
+3.11%
制药与医学研究
+3.01%

热门股票

代码
价格
涨跌幅

ORMP 简况

Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed’s delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company’s products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.
展开

微牛提供Oramed Pharmaceuticals, Inc.(NASDAQ-ORMP)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ORMP股票新闻,以帮助您做出投资决策。